SELLAS Life Sciences Group Inc. (NASDAQ: SLS ) stock is trading higher on Thursday. Year-to-date, the stock has surged by around 300%.
FDA Approval Catalyst For Pancreatic Cancer
SLS’s momentum on Thursday may be related to the U.S. Food and Drug Administration (FDA) on Wednesday approving Revolution Medicines Inc.’s (NASDAQ: RVMD ) Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma (PDAC) . Revolution Medicines’ stock is up over 2% on Thursday.
Specifically, it targets patients who previously underwent at least one systemic therapy or those ineligible for multiagent systemic treatment .
Rasonque marks the first approved targeted cancer therapy from a new class of RAS(ON) multi-selective and mutant-selective inhibitors .
Read Next Trading IdeasRevolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results
Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90% tumor inhibition and extended survival.
2 min read Read this articleSLS009 Preclinical Potential In Solid Tumors
Investors should note that SELLAS is developing SLS009 primarily for earlier-line acute myeloid leukemia (AML) with a potential for expansion into solid cancers.
TrendingSLS009 has demonstrated the ability to act as a single agent in PDAC cells largely resistant to leading RAS inhibitors and to synergize with the RAS inhibition mechanism of action.
The data from these preclinical experiments are expected to be presented at an upcoming medical conference.
Phase 2 AML Trial Progress And Milestones
SELLAS also highlighted progress with SLS009 , including the launch of an 80-patient Phase 2 study in newly diagnosed AML patients considered unlikely to benefit from standard therapies such as AZA/VEN treatment.
Topline data from the study are expected in the fourth quarter of 2026.
According to SELLAS, the data also showed reductions in MCL-1 and surviving levels following treatment .
SLS Stock Price Activity: SELLAS Life Sciences shares were up 10.38% at $15.15 on Thursday, according to Benzinga Pro data .
Photo: lucadp / Shutterstock – ek
Read Next MarketsBlackRock's Exec Says CLARITY Act Is 'Less Critical' for Bitcoin Other Cryptos
BlackRock says the Clarity Act matters less for Bitcoin as institutions increasingly treat BTC like digital gold.
2 min read Read this article Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Trading Ideas Movers News General Biotech Health Care Why It's Moving